The FACT Project Consortium:
A worldwide collaboration to develop and deliver new malaria treatments

The FACT (Fixed-Dose Artesunate Combination Therapy) Project began in 2002 -under the umbrella of MSF (and then DNDi) in coordination with TDR- as there was a clear public health need for a fixed-dose combination of AS and MQ in Latin Amercia and Southeast Asia, and yet there were no other entities interested in developing a response to the need.

 

 Key partners include:

  • Instituto de Tecnologia em Fármacos of Farmanguinhos/Fiocruz
  • Mahidol University
  • Université Victor Segalen Bordeaux 2 (TROPIVAL),
  • University of Oxford
  • University Sains Malaysia
  • the Shoklo Malaria Research Unit
  • the Mae Sot Clinic,
  • MSF
  • DNDi
  • Cipla Ltd.
 

 

DNDi plays an active role to facilitate FACT development and implementation by engaging partners such as pharmaceutical companies, national malaria programmes, research institutes, contract research organisations, and NGOs, as well as the WHO and TDR. DNDi convened an independent panel of experts, the FACT Implementation Advisory Group, who meets on an annual basis to provide external advice and critical guidance on development and facilitation of rational use and equitable access.

Download More about the FACT Project Consortium for ASMQ [PDF] [165KB]